Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y3E5
UPID:
PTH2_HUMAN
Alternative names:
Bcl-2 inhibitor of transcription 1
Alternative UPACC:
Q9Y3E5; B3KUY4; Q9NTE5
Background:
Peptidyl-tRNA hydrolase 2, mitochondrial, also known as Bcl-2 inhibitor of transcription 1, plays a crucial role in protein synthesis by hydrolyzing peptidyl-tRNAs that detach from the ribosome. Additionally, it promotes caspase-independent apoptosis, influencing transcriptional regulators AES and TLE1.
Therapeutic significance:
Linked to Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1, understanding the role of Peptidyl-tRNA hydrolase 2 could open doors to potential therapeutic strategies.